Global Monoclonal Antibodies (mAbs) Biosimilars Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Monoclonal Antibodies (mAbs) Biosimilars market size was valued at US$ 15383 million in 2025 and is forecast to a readjusted size of US$ 47538 million by 2032 with a CAGR of 16.8% during review period.
Monoclonal antibody (mAb) biosimilars are highly similar, lower-cost versions of approved, brand-name biological drugs used to treat cancers, autoimmune diseases, and infections. They are developed after a reference mAb's patent expires and are proven to have no clinically meaningful differences in efficacy, safety, or quality compared to the original, providing greater patient access to advanced therapies.
The global supply structure has become increasingly multi-polar. SouthKorean companies such as Celltrion and SamsungBioepis have built broad, globally visible portfolios across immunology, oncology, ophthalmology and hematology. Large western pharmaceutical and generic groups such as Amgen, Pfizer, Sandoz, FreseniusKabi, Organon and BoehringerIngelheim compete through regulatory scale, commercialization networks and established healthcare-system access. Indian companies such as BioconBiologics, Dr.Reddy’s, Intas/Accord and Lupin combine cost-competitive development with growing regulated-market ambitions. Chinese companies such as Henlius, Bio-Thera, Qilu and Innovent are moving from domestic approvals toward international filings and licensing partnerships. The market is also shaped by partnership models, such as Alvotech/Teva, Formycon/FreseniusKabi, Bio-Thera/STADA and Bio-Thera/GedeonRichter, where one party often leads development and manufacturing while another leads regional commercialization.
Demand growth is being driven by the expansion of biosimilar competition into high-spend reference biologics. The first major wave centered on oncology and immunology products such as trastuzumab, bevacizumab, rituximab, infliximab and adalimumab. The next wave is expanding into ustekinumab, tocilizumab, ranibizumab, aflibercept, denosumab, eculizumab, omalizumab and other antibody-related products. However, regulatory approval alone does not guarantee rapid uptake. The ASPE report on U.S. biosimilar market entry highlights that market size and entry order affect biosimilar revenues, and that markets such as bevacizumab, rituximab and trastuzumab took time to reach peak biosimilar share. In practice, adoption depends on payer policy, tendering rules, formulary access, physician confidence, patient switching, interchangeability status, originator contracting and supply reliability.
From a product and strategy perspective, the market is moving beyond simple “first biosimilar to a blockbuster mAb” competition. Future differentiation will increasingly depend on high-concentration formulations, citrate-free presentations, prefilled syringes, autoinjectors, interchangeability designations, global dossier reuse, real-world evidence, manufacturing cost control and broad market-access execution. The U.S. and Europe will remain the most valuable regulated markets, but China, India, Latin America, the Middle East and Southeast Asia are increasingly important for volume growth and regional commercialization partnerships. The long-term outlook is positive because many high-value biologics are entering or approaching biosimilar competition, but price erosion can be severe once multiple entrants compete. Companies with integrated R&D, manufacturing, regulatory and commercialization capabilities are therefore better positioned than firms that rely only on low-cost production or single-market approvals.
This report is a detailed and comprehensive analysis for global Monoclonal Antibodies (mAbs) Biosimilars market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Monoclonal Antibodies (mAbs) Biosimilars market size and forecasts, in consumption value ($ Million), 2021-2032
Global Monoclonal Antibodies (mAbs) Biosimilars market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Monoclonal Antibodies (mAbs) Biosimilars market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Monoclonal Antibodies (mAbs) Biosimilars market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Monoclonal Antibodies (mAbs) Biosimilars market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Monoclonal Antibodies (mAbs) Biosimilars product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Monoclonal Antibodies (mAbs) Biosimilars, with revenue, gross margin, and global market share of Monoclonal Antibodies (mAbs) Biosimilars from 2021 to 2026.
Chapter 3, the Monoclonal Antibodies (mAbs) Biosimilars competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Monoclonal Antibodies (mAbs) Biosimilars market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Monoclonal Antibodies (mAbs) Biosimilars.
Chapter 13, to describe Monoclonal Antibodies (mAbs) Biosimilars research findings and conclusion.
Monoclonal antibody (mAb) biosimilars are highly similar, lower-cost versions of approved, brand-name biological drugs used to treat cancers, autoimmune diseases, and infections. They are developed after a reference mAb's patent expires and are proven to have no clinically meaningful differences in efficacy, safety, or quality compared to the original, providing greater patient access to advanced therapies.
The global supply structure has become increasingly multi-polar. SouthKorean companies such as Celltrion and SamsungBioepis have built broad, globally visible portfolios across immunology, oncology, ophthalmology and hematology. Large western pharmaceutical and generic groups such as Amgen, Pfizer, Sandoz, FreseniusKabi, Organon and BoehringerIngelheim compete through regulatory scale, commercialization networks and established healthcare-system access. Indian companies such as BioconBiologics, Dr.Reddy’s, Intas/Accord and Lupin combine cost-competitive development with growing regulated-market ambitions. Chinese companies such as Henlius, Bio-Thera, Qilu and Innovent are moving from domestic approvals toward international filings and licensing partnerships. The market is also shaped by partnership models, such as Alvotech/Teva, Formycon/FreseniusKabi, Bio-Thera/STADA and Bio-Thera/GedeonRichter, where one party often leads development and manufacturing while another leads regional commercialization.
Demand growth is being driven by the expansion of biosimilar competition into high-spend reference biologics. The first major wave centered on oncology and immunology products such as trastuzumab, bevacizumab, rituximab, infliximab and adalimumab. The next wave is expanding into ustekinumab, tocilizumab, ranibizumab, aflibercept, denosumab, eculizumab, omalizumab and other antibody-related products. However, regulatory approval alone does not guarantee rapid uptake. The ASPE report on U.S. biosimilar market entry highlights that market size and entry order affect biosimilar revenues, and that markets such as bevacizumab, rituximab and trastuzumab took time to reach peak biosimilar share. In practice, adoption depends on payer policy, tendering rules, formulary access, physician confidence, patient switching, interchangeability status, originator contracting and supply reliability.
From a product and strategy perspective, the market is moving beyond simple “first biosimilar to a blockbuster mAb” competition. Future differentiation will increasingly depend on high-concentration formulations, citrate-free presentations, prefilled syringes, autoinjectors, interchangeability designations, global dossier reuse, real-world evidence, manufacturing cost control and broad market-access execution. The U.S. and Europe will remain the most valuable regulated markets, but China, India, Latin America, the Middle East and Southeast Asia are increasingly important for volume growth and regional commercialization partnerships. The long-term outlook is positive because many high-value biologics are entering or approaching biosimilar competition, but price erosion can be severe once multiple entrants compete. Companies with integrated R&D, manufacturing, regulatory and commercialization capabilities are therefore better positioned than firms that rely only on low-cost production or single-market approvals.
This report is a detailed and comprehensive analysis for global Monoclonal Antibodies (mAbs) Biosimilars market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Monoclonal Antibodies (mAbs) Biosimilars market size and forecasts, in consumption value ($ Million), 2021-2032
Global Monoclonal Antibodies (mAbs) Biosimilars market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Monoclonal Antibodies (mAbs) Biosimilars market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Monoclonal Antibodies (mAbs) Biosimilars market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Monoclonal Antibodies (mAbs) Biosimilars
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Monoclonal Antibodies (mAbs) Biosimilars market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Adalimumab Biosimilars
- Infliximab Biosimilars
- Rituximab Biosimilars
- Trastuzumab Biosimilars
- Bevacizumab Biosimilars
- Ranibizumab Biosimilars
- Ustekinumab Biosimilars
- Tocilizumab Biosimilars
- Denosumab Biosimilars
- Other mAb Biosimilars
- Intravenous Infusion Vials
- Subcutaneous Prefilled Syringes
- Autoinjectors
- Lyophilized Powder for Injection
- Concentrate for Solution for Infusion
- Ophthalmic Intravitreal Injection
- Multiple Presentations
- TNF-? Inhibitors
- CD20-targeting Antibodies
- HER2-targeting Antibodies
- VEGF/VEGF-A Inhibitors
- IL-6R Inhibitors
- IL-12/23 Inhibitors
- RANKL Inhibitors
- C5 Complement Inhibitors
- IgE Inhibitors
- Other Targets
- Oncology
- Autoimmune and Inflammatory Diseases
- Ophthalmology
- Bone Disease and Osteoporosis
- Hematology and Rare Diseases
- Asthma and Allergy
- Other
- Celltrion,Inc.
- SamsungBioepisCo.,Ltd.
- AmgenInc.
- SandozGroupAG
- PfizerInc.
- BioconBiologicsLimited
- FreseniusKabiAG
- FormyconAG
- Alvotech
- TevaPharmaceuticalIndustriesLtd.
- Organon&Co.
- BoehringerIngelheimInternationalGmbH
- CoherusBioSciences,Inc.
- mAbxience
- STADAArzneimittelAG
- GedeonRichterPlc.
- Bio-TheraSolutions,Ltd.
- ShanghaiHenliusBiotech,Inc.
- QiluPharmaceuticalCo.,Ltd.
- InnoventBiologics,Inc.
- Dr.Reddy’sLaboratoriesLtd.
- IntasPharmaceuticalsLtd.
- AccordHealthcare
- LupinLimited
- ZydusLifesciencesLimited
- RelianceLifeSciencesPvt.Ltd.
- PrestigeBiopharmaLimited
- AmnealPharmaceuticals,Inc.
- PolpharmaBiologicsB.V.
- Mabwell(Shanghai)BioscienceCo.,Ltd.
- ZhejiangHisunPharmaceuticalCo.,Ltd.
- JiangsuHengruiPharmaceuticalsCo.,Ltd.
- LivzonPharmaceuticalGroupInc.
- SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd.
- MabpharmLimited
- BioXpressTherapeuticsSA
- TanvexBioPharma,Inc.
- CelltrionHealthcare
- AmegaBiotech
- ProbiomedS.A.deC.V.
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Monoclonal Antibodies (mAbs) Biosimilars product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Monoclonal Antibodies (mAbs) Biosimilars, with revenue, gross margin, and global market share of Monoclonal Antibodies (mAbs) Biosimilars from 2021 to 2026.
Chapter 3, the Monoclonal Antibodies (mAbs) Biosimilars competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Monoclonal Antibodies (mAbs) Biosimilars market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Monoclonal Antibodies (mAbs) Biosimilars.
Chapter 13, to describe Monoclonal Antibodies (mAbs) Biosimilars research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Monoclonal Antibodies (mAbs) Biosimilars by Type
1.3.1 Overview: Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Type in 2025
1.3.3 Adalimumab Biosimilars
1.3.4 Infliximab Biosimilars
1.3.5 Rituximab Biosimilars
1.3.6 Trastuzumab Biosimilars
1.3.7 Bevacizumab Biosimilars
1.3.8 Ranibizumab Biosimilars
1.3.9 Ustekinumab Biosimilars
1.3.10 Tocilizumab Biosimilars
1.3.11 Denosumab Biosimilars
1.4 Classification of Monoclonal Antibodies (mAbs) Biosimilars by Dosage Form
1.4.1 Overview: Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Dosage Form: 2021 Versus 2025 Versus 2032
1.4.2 Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Dosage Form in 2025
1.4.3 Intravenous Infusion Vials
1.4.4 Subcutaneous Prefilled Syringes
1.4.5 Autoinjectors
1.4.6 Lyophilized Powder for Injection
1.4.7 Concentrate for Solution for Infusion
1.4.8 Ophthalmic Intravitreal Injection
1.4.9 Multiple Presentations
1.5 Classification of Monoclonal Antibodies (mAbs) Biosimilars by Molecular Target
1.5.1 Overview: Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Molecular Target: 2021 Versus 2025 Versus 2032
1.5.2 Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Molecular Target in 2025
1.5.3 TNF-? Inhibitors
1.5.4 CD20-targeting Antibodies
1.5.5 HER2-targeting Antibodies
1.5.6 VEGF/VEGF-A Inhibitors
1.5.7 IL-6R Inhibitors
1.5.8 IL-12/23 Inhibitors
1.5.9 RANKL Inhibitors
1.5.10 C5 Complement Inhibitors
1.5.11 IgE Inhibitors
1.6 Global Monoclonal Antibodies (mAbs) Biosimilars Market by Application
1.6.1 Overview: Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Oncology
1.6.3 Autoimmune and Inflammatory Diseases
1.6.4 Ophthalmology
1.6.5 Bone Disease and Osteoporosis
1.6.6 Hematology and Rare Diseases
1.6.7 Asthma and Allergy
1.6.8 Other
1.7 Global Monoclonal Antibodies (mAbs) Biosimilars Market Size & Forecast
1.8 Global Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast by Region
1.8.1 Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Region, (2021-2032)
1.8.3 North America Monoclonal Antibodies (mAbs) Biosimilars Market Size and Prospect (2021-2032)
1.8.4 Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Market Size and Prospect (2021-2032)
1.8.6 South America Monoclonal Antibodies (mAbs) Biosimilars Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Celltrion,Inc.
2.1.1 Celltrion,Inc. Details
2.1.2 Celltrion,Inc. Major Business
2.1.3 Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.1.4 Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Celltrion,Inc. Recent Developments and Future Plans
2.2 SamsungBioepisCo.,Ltd.
2.2.1 SamsungBioepisCo.,Ltd. Details
2.2.2 SamsungBioepisCo.,Ltd. Major Business
2.2.3 SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.2.4 SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 SamsungBioepisCo.,Ltd. Recent Developments and Future Plans
2.3 AmgenInc.
2.3.1 AmgenInc. Details
2.3.2 AmgenInc. Major Business
2.3.3 AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.3.4 AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 AmgenInc. Recent Developments and Future Plans
2.4 SandozGroupAG
2.4.1 SandozGroupAG Details
2.4.2 SandozGroupAG Major Business
2.4.3 SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.4.4 SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 SandozGroupAG Recent Developments and Future Plans
2.5 PfizerInc.
2.5.1 PfizerInc. Details
2.5.2 PfizerInc. Major Business
2.5.3 PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.5.4 PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 PfizerInc. Recent Developments and Future Plans
2.6 BioconBiologicsLimited
2.6.1 BioconBiologicsLimited Details
2.6.2 BioconBiologicsLimited Major Business
2.6.3 BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.6.4 BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 BioconBiologicsLimited Recent Developments and Future Plans
2.7 FreseniusKabiAG
2.7.1 FreseniusKabiAG Details
2.7.2 FreseniusKabiAG Major Business
2.7.3 FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.7.4 FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 FreseniusKabiAG Recent Developments and Future Plans
2.8 FormyconAG
2.8.1 FormyconAG Details
2.8.2 FormyconAG Major Business
2.8.3 FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.8.4 FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 FormyconAG Recent Developments and Future Plans
2.9 Alvotech
2.9.1 Alvotech Details
2.9.2 Alvotech Major Business
2.9.3 Alvotech Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.9.4 Alvotech Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Alvotech Recent Developments and Future Plans
2.10 TevaPharmaceuticalIndustriesLtd.
2.10.1 TevaPharmaceuticalIndustriesLtd. Details
2.10.2 TevaPharmaceuticalIndustriesLtd. Major Business
2.10.3 TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.10.4 TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 TevaPharmaceuticalIndustriesLtd. Recent Developments and Future Plans
2.11 Organon&Co.
2.11.1 Organon&Co. Details
2.11.2 Organon&Co. Major Business
2.11.3 Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.11.4 Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Organon&Co. Recent Developments and Future Plans
2.12 BoehringerIngelheimInternationalGmbH
2.12.1 BoehringerIngelheimInternationalGmbH Details
2.12.2 BoehringerIngelheimInternationalGmbH Major Business
2.12.3 BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.12.4 BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 BoehringerIngelheimInternationalGmbH Recent Developments and Future Plans
2.13 CoherusBioSciences,Inc.
2.13.1 CoherusBioSciences,Inc. Details
2.13.2 CoherusBioSciences,Inc. Major Business
2.13.3 CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.13.4 CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 CoherusBioSciences,Inc. Recent Developments and Future Plans
2.14 mAbxience
2.14.1 mAbxience Details
2.14.2 mAbxience Major Business
2.14.3 mAbxience Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.14.4 mAbxience Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 mAbxience Recent Developments and Future Plans
2.15 STADAArzneimittelAG
2.15.1 STADAArzneimittelAG Details
2.15.2 STADAArzneimittelAG Major Business
2.15.3 STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.15.4 STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 STADAArzneimittelAG Recent Developments and Future Plans
2.16 GedeonRichterPlc.
2.16.1 GedeonRichterPlc. Details
2.16.2 GedeonRichterPlc. Major Business
2.16.3 GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.16.4 GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 GedeonRichterPlc. Recent Developments and Future Plans
2.17 Bio-TheraSolutions,Ltd.
2.17.1 Bio-TheraSolutions,Ltd. Details
2.17.2 Bio-TheraSolutions,Ltd. Major Business
2.17.3 Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.17.4 Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 Bio-TheraSolutions,Ltd. Recent Developments and Future Plans
2.18 ShanghaiHenliusBiotech,Inc.
2.18.1 ShanghaiHenliusBiotech,Inc. Details
2.18.2 ShanghaiHenliusBiotech,Inc. Major Business
2.18.3 ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.18.4 ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 ShanghaiHenliusBiotech,Inc. Recent Developments and Future Plans
2.19 QiluPharmaceuticalCo.,Ltd.
2.19.1 QiluPharmaceuticalCo.,Ltd. Details
2.19.2 QiluPharmaceuticalCo.,Ltd. Major Business
2.19.3 QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.19.4 QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.19.5 QiluPharmaceuticalCo.,Ltd. Recent Developments and Future Plans
2.20 InnoventBiologics,Inc.
2.20.1 InnoventBiologics,Inc. Details
2.20.2 InnoventBiologics,Inc. Major Business
2.20.3 InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.20.4 InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.20.5 InnoventBiologics,Inc. Recent Developments and Future Plans
2.21 Dr.Reddy’sLaboratoriesLtd.
2.21.1 Dr.Reddy’sLaboratoriesLtd. Details
2.21.2 Dr.Reddy’sLaboratoriesLtd. Major Business
2.21.3 Dr.Reddy’sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.21.4 Dr.Reddy’sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.21.5 Dr.Reddy’sLaboratoriesLtd. Recent Developments and Future Plans
2.22 IntasPharmaceuticalsLtd.
2.22.1 IntasPharmaceuticalsLtd. Details
2.22.2 IntasPharmaceuticalsLtd. Major Business
2.22.3 IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.22.4 IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.22.5 IntasPharmaceuticalsLtd. Recent Developments and Future Plans
2.23 AccordHealthcare
2.23.1 AccordHealthcare Details
2.23.2 AccordHealthcare Major Business
2.23.3 AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.23.4 AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.23.5 AccordHealthcare Recent Developments and Future Plans
2.24 LupinLimited
2.24.1 LupinLimited Details
2.24.2 LupinLimited Major Business
2.24.3 LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.24.4 LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.24.5 LupinLimited Recent Developments and Future Plans
2.25 ZydusLifesciencesLimited
2.25.1 ZydusLifesciencesLimited Details
2.25.2 ZydusLifesciencesLimited Major Business
2.25.3 ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.25.4 ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.25.5 ZydusLifesciencesLimited Recent Developments and Future Plans
2.26 RelianceLifeSciencesPvt.Ltd.
2.26.1 RelianceLifeSciencesPvt.Ltd. Details
2.26.2 RelianceLifeSciencesPvt.Ltd. Major Business
2.26.3 RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.26.4 RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.26.5 RelianceLifeSciencesPvt.Ltd. Recent Developments and Future Plans
2.27 PrestigeBiopharmaLimited
2.27.1 PrestigeBiopharmaLimited Details
2.27.2 PrestigeBiopharmaLimited Major Business
2.27.3 PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.27.4 PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.27.5 PrestigeBiopharmaLimited Recent Developments and Future Plans
2.28 AmnealPharmaceuticals,Inc.
2.28.1 AmnealPharmaceuticals,Inc. Details
2.28.2 AmnealPharmaceuticals,Inc. Major Business
2.28.3 AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.28.4 AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.28.5 AmnealPharmaceuticals,Inc. Recent Developments and Future Plans
2.29 PolpharmaBiologicsB.V.
2.29.1 PolpharmaBiologicsB.V. Details
2.29.2 PolpharmaBiologicsB.V. Major Business
2.29.3 PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.29.4 PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.29.5 PolpharmaBiologicsB.V. Recent Developments and Future Plans
2.30 Mabwell(Shanghai)BioscienceCo.,Ltd.
2.30.1 Mabwell(Shanghai)BioscienceCo.,Ltd. Details
2.30.2 Mabwell(Shanghai)BioscienceCo.,Ltd. Major Business
2.30.3 Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.30.4 Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.30.5 Mabwell(Shanghai)BioscienceCo.,Ltd. Recent Developments and Future Plans
2.31 ZhejiangHisunPharmaceuticalCo.,Ltd.
2.31.1 ZhejiangHisunPharmaceuticalCo.,Ltd. Details
2.31.2 ZhejiangHisunPharmaceuticalCo.,Ltd. Major Business
2.31.3 ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.31.4 ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.31.5 ZhejiangHisunPharmaceuticalCo.,Ltd. Recent Developments and Future Plans
2.32 JiangsuHengruiPharmaceuticalsCo.,Ltd.
2.32.1 JiangsuHengruiPharmaceuticalsCo.,Ltd. Details
2.32.2 JiangsuHengruiPharmaceuticalsCo.,Ltd. Major Business
2.32.3 JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.32.4 JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.32.5 JiangsuHengruiPharmaceuticalsCo.,Ltd. Recent Developments and Future Plans
2.33 LivzonPharmaceuticalGroupInc.
2.33.1 LivzonPharmaceuticalGroupInc. Details
2.33.2 LivzonPharmaceuticalGroupInc. Major Business
2.33.3 LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.33.4 LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.33.5 LivzonPharmaceuticalGroupInc. Recent Developments and Future Plans
2.34 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd.
2.34.1 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Details
2.34.2 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Major Business
2.34.3 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.34.4 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.34.5 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Recent Developments and Future Plans
2.35 MabpharmLimited
2.35.1 MabpharmLimited Details
2.35.2 MabpharmLimited Major Business
2.35.3 MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.35.4 MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.35.5 MabpharmLimited Recent Developments and Future Plans
2.36 BioXpressTherapeuticsSA
2.36.1 BioXpressTherapeuticsSA Details
2.36.2 BioXpressTherapeuticsSA Major Business
2.36.3 BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.36.4 BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.36.5 BioXpressTherapeuticsSA Recent Developments and Future Plans
2.37 TanvexBioPharma,Inc.
2.37.1 TanvexBioPharma,Inc. Details
2.37.2 TanvexBioPharma,Inc. Major Business
2.37.3 TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.37.4 TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.37.5 TanvexBioPharma,Inc. Recent Developments and Future Plans
2.38 CelltrionHealthcare
2.38.1 CelltrionHealthcare Details
2.38.2 CelltrionHealthcare Major Business
2.38.3 CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.38.4 CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.38.5 CelltrionHealthcare Recent Developments and Future Plans
2.39 AmegaBiotech
2.39.1 AmegaBiotech Details
2.39.2 AmegaBiotech Major Business
2.39.3 AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.39.4 AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.39.5 AmegaBiotech Recent Developments and Future Plans
2.40 ProbiomedS.A.deC.V.
2.40.1 ProbiomedS.A.deC.V. Details
2.40.2 ProbiomedS.A.deC.V. Major Business
2.40.3 ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.40.4 ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.40.5 ProbiomedS.A.deC.V. Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Monoclonal Antibodies (mAbs) Biosimilars Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Monoclonal Antibodies (mAbs) Biosimilars by Company Revenue
3.2.2 Top 3 Monoclonal Antibodies (mAbs) Biosimilars Players Market Share in 2025
3.2.3 Top 6 Monoclonal Antibodies (mAbs) Biosimilars Players Market Share in 2025
3.3 Monoclonal Antibodies (mAbs) Biosimilars Market: Overall Company Footprint Analysis
3.3.1 Monoclonal Antibodies (mAbs) Biosimilars Market: Region Footprint
3.3.2 Monoclonal Antibodies (mAbs) Biosimilars Market: Company Product Type Footprint
3.3.3 Monoclonal Antibodies (mAbs) Biosimilars Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value and Market Share by Type (2021-2026)
4.2 Global Monoclonal Antibodies (mAbs) Biosimilars Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Application (2021-2026)
5.2 Global Monoclonal Antibodies (mAbs) Biosimilars Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2021-2032)
6.2 North America Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2032)
6.3 North America Monoclonal Antibodies (mAbs) Biosimilars Market Size by Country
6.3.1 North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2021-2032)
6.3.2 United States Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
6.3.3 Canada Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
6.3.4 Mexico Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2021-2032)
7.2 Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2021-2032)
7.3 Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size by Country
7.3.1 Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2021-2032)
7.3.2 Germany Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
7.3.3 France Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
7.3.5 Russia Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
7.3.6 Italy Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Market Size by Region
8.3.1 Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Region (2021-2032)
8.3.2 China Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
8.3.3 Japan Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
8.3.4 South Korea Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
8.3.5 India Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
8.3.7 Australia Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2021-2032)
9.2 South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2021-2032)
9.3 South America Monoclonal Antibodies (mAbs) Biosimilars Market Size by Country
9.3.1 South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2021-2032)
9.3.2 Brazil Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
9.3.3 Argentina Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size by Country
10.3.1 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2021-2032)
10.3.2 Turkey Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
10.3.4 UAE Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Monoclonal Antibodies (mAbs) Biosimilars Market Drivers
11.2 Monoclonal Antibodies (mAbs) Biosimilars Market Restraints
11.3 Monoclonal Antibodies (mAbs) Biosimilars Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Monoclonal Antibodies (mAbs) Biosimilars Industry Chain
12.2 Monoclonal Antibodies (mAbs) Biosimilars Upstream Analysis
12.3 Monoclonal Antibodies (mAbs) Biosimilars Midstream Analysis
12.4 Monoclonal Antibodies (mAbs) Biosimilars Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Monoclonal Antibodies (mAbs) Biosimilars by Type
1.3.1 Overview: Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Type in 2025
1.3.3 Adalimumab Biosimilars
1.3.4 Infliximab Biosimilars
1.3.5 Rituximab Biosimilars
1.3.6 Trastuzumab Biosimilars
1.3.7 Bevacizumab Biosimilars
1.3.8 Ranibizumab Biosimilars
1.3.9 Ustekinumab Biosimilars
1.3.10 Tocilizumab Biosimilars
1.3.11 Denosumab Biosimilars
1.4 Classification of Monoclonal Antibodies (mAbs) Biosimilars by Dosage Form
1.4.1 Overview: Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Dosage Form: 2021 Versus 2025 Versus 2032
1.4.2 Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Dosage Form in 2025
1.4.3 Intravenous Infusion Vials
1.4.4 Subcutaneous Prefilled Syringes
1.4.5 Autoinjectors
1.4.6 Lyophilized Powder for Injection
1.4.7 Concentrate for Solution for Infusion
1.4.8 Ophthalmic Intravitreal Injection
1.4.9 Multiple Presentations
1.5 Classification of Monoclonal Antibodies (mAbs) Biosimilars by Molecular Target
1.5.1 Overview: Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Molecular Target: 2021 Versus 2025 Versus 2032
1.5.2 Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Molecular Target in 2025
1.5.3 TNF-? Inhibitors
1.5.4 CD20-targeting Antibodies
1.5.5 HER2-targeting Antibodies
1.5.6 VEGF/VEGF-A Inhibitors
1.5.7 IL-6R Inhibitors
1.5.8 IL-12/23 Inhibitors
1.5.9 RANKL Inhibitors
1.5.10 C5 Complement Inhibitors
1.5.11 IgE Inhibitors
1.6 Global Monoclonal Antibodies (mAbs) Biosimilars Market by Application
1.6.1 Overview: Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Oncology
1.6.3 Autoimmune and Inflammatory Diseases
1.6.4 Ophthalmology
1.6.5 Bone Disease and Osteoporosis
1.6.6 Hematology and Rare Diseases
1.6.7 Asthma and Allergy
1.6.8 Other
1.7 Global Monoclonal Antibodies (mAbs) Biosimilars Market Size & Forecast
1.8 Global Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast by Region
1.8.1 Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Monoclonal Antibodies (mAbs) Biosimilars Market Size by Region, (2021-2032)
1.8.3 North America Monoclonal Antibodies (mAbs) Biosimilars Market Size and Prospect (2021-2032)
1.8.4 Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Market Size and Prospect (2021-2032)
1.8.6 South America Monoclonal Antibodies (mAbs) Biosimilars Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Celltrion,Inc.
2.1.1 Celltrion,Inc. Details
2.1.2 Celltrion,Inc. Major Business
2.1.3 Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.1.4 Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Celltrion,Inc. Recent Developments and Future Plans
2.2 SamsungBioepisCo.,Ltd.
2.2.1 SamsungBioepisCo.,Ltd. Details
2.2.2 SamsungBioepisCo.,Ltd. Major Business
2.2.3 SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.2.4 SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 SamsungBioepisCo.,Ltd. Recent Developments and Future Plans
2.3 AmgenInc.
2.3.1 AmgenInc. Details
2.3.2 AmgenInc. Major Business
2.3.3 AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.3.4 AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 AmgenInc. Recent Developments and Future Plans
2.4 SandozGroupAG
2.4.1 SandozGroupAG Details
2.4.2 SandozGroupAG Major Business
2.4.3 SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.4.4 SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 SandozGroupAG Recent Developments and Future Plans
2.5 PfizerInc.
2.5.1 PfizerInc. Details
2.5.2 PfizerInc. Major Business
2.5.3 PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.5.4 PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 PfizerInc. Recent Developments and Future Plans
2.6 BioconBiologicsLimited
2.6.1 BioconBiologicsLimited Details
2.6.2 BioconBiologicsLimited Major Business
2.6.3 BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.6.4 BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 BioconBiologicsLimited Recent Developments and Future Plans
2.7 FreseniusKabiAG
2.7.1 FreseniusKabiAG Details
2.7.2 FreseniusKabiAG Major Business
2.7.3 FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.7.4 FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 FreseniusKabiAG Recent Developments and Future Plans
2.8 FormyconAG
2.8.1 FormyconAG Details
2.8.2 FormyconAG Major Business
2.8.3 FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.8.4 FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 FormyconAG Recent Developments and Future Plans
2.9 Alvotech
2.9.1 Alvotech Details
2.9.2 Alvotech Major Business
2.9.3 Alvotech Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.9.4 Alvotech Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Alvotech Recent Developments and Future Plans
2.10 TevaPharmaceuticalIndustriesLtd.
2.10.1 TevaPharmaceuticalIndustriesLtd. Details
2.10.2 TevaPharmaceuticalIndustriesLtd. Major Business
2.10.3 TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.10.4 TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 TevaPharmaceuticalIndustriesLtd. Recent Developments and Future Plans
2.11 Organon&Co.
2.11.1 Organon&Co. Details
2.11.2 Organon&Co. Major Business
2.11.3 Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.11.4 Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Organon&Co. Recent Developments and Future Plans
2.12 BoehringerIngelheimInternationalGmbH
2.12.1 BoehringerIngelheimInternationalGmbH Details
2.12.2 BoehringerIngelheimInternationalGmbH Major Business
2.12.3 BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.12.4 BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 BoehringerIngelheimInternationalGmbH Recent Developments and Future Plans
2.13 CoherusBioSciences,Inc.
2.13.1 CoherusBioSciences,Inc. Details
2.13.2 CoherusBioSciences,Inc. Major Business
2.13.3 CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.13.4 CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 CoherusBioSciences,Inc. Recent Developments and Future Plans
2.14 mAbxience
2.14.1 mAbxience Details
2.14.2 mAbxience Major Business
2.14.3 mAbxience Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.14.4 mAbxience Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 mAbxience Recent Developments and Future Plans
2.15 STADAArzneimittelAG
2.15.1 STADAArzneimittelAG Details
2.15.2 STADAArzneimittelAG Major Business
2.15.3 STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.15.4 STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 STADAArzneimittelAG Recent Developments and Future Plans
2.16 GedeonRichterPlc.
2.16.1 GedeonRichterPlc. Details
2.16.2 GedeonRichterPlc. Major Business
2.16.3 GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.16.4 GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 GedeonRichterPlc. Recent Developments and Future Plans
2.17 Bio-TheraSolutions,Ltd.
2.17.1 Bio-TheraSolutions,Ltd. Details
2.17.2 Bio-TheraSolutions,Ltd. Major Business
2.17.3 Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.17.4 Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 Bio-TheraSolutions,Ltd. Recent Developments and Future Plans
2.18 ShanghaiHenliusBiotech,Inc.
2.18.1 ShanghaiHenliusBiotech,Inc. Details
2.18.2 ShanghaiHenliusBiotech,Inc. Major Business
2.18.3 ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.18.4 ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 ShanghaiHenliusBiotech,Inc. Recent Developments and Future Plans
2.19 QiluPharmaceuticalCo.,Ltd.
2.19.1 QiluPharmaceuticalCo.,Ltd. Details
2.19.2 QiluPharmaceuticalCo.,Ltd. Major Business
2.19.3 QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.19.4 QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.19.5 QiluPharmaceuticalCo.,Ltd. Recent Developments and Future Plans
2.20 InnoventBiologics,Inc.
2.20.1 InnoventBiologics,Inc. Details
2.20.2 InnoventBiologics,Inc. Major Business
2.20.3 InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.20.4 InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.20.5 InnoventBiologics,Inc. Recent Developments and Future Plans
2.21 Dr.Reddy’sLaboratoriesLtd.
2.21.1 Dr.Reddy’sLaboratoriesLtd. Details
2.21.2 Dr.Reddy’sLaboratoriesLtd. Major Business
2.21.3 Dr.Reddy’sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.21.4 Dr.Reddy’sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.21.5 Dr.Reddy’sLaboratoriesLtd. Recent Developments and Future Plans
2.22 IntasPharmaceuticalsLtd.
2.22.1 IntasPharmaceuticalsLtd. Details
2.22.2 IntasPharmaceuticalsLtd. Major Business
2.22.3 IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.22.4 IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.22.5 IntasPharmaceuticalsLtd. Recent Developments and Future Plans
2.23 AccordHealthcare
2.23.1 AccordHealthcare Details
2.23.2 AccordHealthcare Major Business
2.23.3 AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.23.4 AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.23.5 AccordHealthcare Recent Developments and Future Plans
2.24 LupinLimited
2.24.1 LupinLimited Details
2.24.2 LupinLimited Major Business
2.24.3 LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.24.4 LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.24.5 LupinLimited Recent Developments and Future Plans
2.25 ZydusLifesciencesLimited
2.25.1 ZydusLifesciencesLimited Details
2.25.2 ZydusLifesciencesLimited Major Business
2.25.3 ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.25.4 ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.25.5 ZydusLifesciencesLimited Recent Developments and Future Plans
2.26 RelianceLifeSciencesPvt.Ltd.
2.26.1 RelianceLifeSciencesPvt.Ltd. Details
2.26.2 RelianceLifeSciencesPvt.Ltd. Major Business
2.26.3 RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.26.4 RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.26.5 RelianceLifeSciencesPvt.Ltd. Recent Developments and Future Plans
2.27 PrestigeBiopharmaLimited
2.27.1 PrestigeBiopharmaLimited Details
2.27.2 PrestigeBiopharmaLimited Major Business
2.27.3 PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.27.4 PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.27.5 PrestigeBiopharmaLimited Recent Developments and Future Plans
2.28 AmnealPharmaceuticals,Inc.
2.28.1 AmnealPharmaceuticals,Inc. Details
2.28.2 AmnealPharmaceuticals,Inc. Major Business
2.28.3 AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.28.4 AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.28.5 AmnealPharmaceuticals,Inc. Recent Developments and Future Plans
2.29 PolpharmaBiologicsB.V.
2.29.1 PolpharmaBiologicsB.V. Details
2.29.2 PolpharmaBiologicsB.V. Major Business
2.29.3 PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.29.4 PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.29.5 PolpharmaBiologicsB.V. Recent Developments and Future Plans
2.30 Mabwell(Shanghai)BioscienceCo.,Ltd.
2.30.1 Mabwell(Shanghai)BioscienceCo.,Ltd. Details
2.30.2 Mabwell(Shanghai)BioscienceCo.,Ltd. Major Business
2.30.3 Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.30.4 Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.30.5 Mabwell(Shanghai)BioscienceCo.,Ltd. Recent Developments and Future Plans
2.31 ZhejiangHisunPharmaceuticalCo.,Ltd.
2.31.1 ZhejiangHisunPharmaceuticalCo.,Ltd. Details
2.31.2 ZhejiangHisunPharmaceuticalCo.,Ltd. Major Business
2.31.3 ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.31.4 ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.31.5 ZhejiangHisunPharmaceuticalCo.,Ltd. Recent Developments and Future Plans
2.32 JiangsuHengruiPharmaceuticalsCo.,Ltd.
2.32.1 JiangsuHengruiPharmaceuticalsCo.,Ltd. Details
2.32.2 JiangsuHengruiPharmaceuticalsCo.,Ltd. Major Business
2.32.3 JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.32.4 JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.32.5 JiangsuHengruiPharmaceuticalsCo.,Ltd. Recent Developments and Future Plans
2.33 LivzonPharmaceuticalGroupInc.
2.33.1 LivzonPharmaceuticalGroupInc. Details
2.33.2 LivzonPharmaceuticalGroupInc. Major Business
2.33.3 LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.33.4 LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.33.5 LivzonPharmaceuticalGroupInc. Recent Developments and Future Plans
2.34 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd.
2.34.1 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Details
2.34.2 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Major Business
2.34.3 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.34.4 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.34.5 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Recent Developments and Future Plans
2.35 MabpharmLimited
2.35.1 MabpharmLimited Details
2.35.2 MabpharmLimited Major Business
2.35.3 MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.35.4 MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.35.5 MabpharmLimited Recent Developments and Future Plans
2.36 BioXpressTherapeuticsSA
2.36.1 BioXpressTherapeuticsSA Details
2.36.2 BioXpressTherapeuticsSA Major Business
2.36.3 BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.36.4 BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.36.5 BioXpressTherapeuticsSA Recent Developments and Future Plans
2.37 TanvexBioPharma,Inc.
2.37.1 TanvexBioPharma,Inc. Details
2.37.2 TanvexBioPharma,Inc. Major Business
2.37.3 TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.37.4 TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.37.5 TanvexBioPharma,Inc. Recent Developments and Future Plans
2.38 CelltrionHealthcare
2.38.1 CelltrionHealthcare Details
2.38.2 CelltrionHealthcare Major Business
2.38.3 CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.38.4 CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.38.5 CelltrionHealthcare Recent Developments and Future Plans
2.39 AmegaBiotech
2.39.1 AmegaBiotech Details
2.39.2 AmegaBiotech Major Business
2.39.3 AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.39.4 AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.39.5 AmegaBiotech Recent Developments and Future Plans
2.40 ProbiomedS.A.deC.V.
2.40.1 ProbiomedS.A.deC.V. Details
2.40.2 ProbiomedS.A.deC.V. Major Business
2.40.3 ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
2.40.4 ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
2.40.5 ProbiomedS.A.deC.V. Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Monoclonal Antibodies (mAbs) Biosimilars Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Monoclonal Antibodies (mAbs) Biosimilars by Company Revenue
3.2.2 Top 3 Monoclonal Antibodies (mAbs) Biosimilars Players Market Share in 2025
3.2.3 Top 6 Monoclonal Antibodies (mAbs) Biosimilars Players Market Share in 2025
3.3 Monoclonal Antibodies (mAbs) Biosimilars Market: Overall Company Footprint Analysis
3.3.1 Monoclonal Antibodies (mAbs) Biosimilars Market: Region Footprint
3.3.2 Monoclonal Antibodies (mAbs) Biosimilars Market: Company Product Type Footprint
3.3.3 Monoclonal Antibodies (mAbs) Biosimilars Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value and Market Share by Type (2021-2026)
4.2 Global Monoclonal Antibodies (mAbs) Biosimilars Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Application (2021-2026)
5.2 Global Monoclonal Antibodies (mAbs) Biosimilars Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2021-2032)
6.2 North America Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2032)
6.3 North America Monoclonal Antibodies (mAbs) Biosimilars Market Size by Country
6.3.1 North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2021-2032)
6.3.2 United States Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
6.3.3 Canada Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
6.3.4 Mexico Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2021-2032)
7.2 Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2021-2032)
7.3 Europe Monoclonal Antibodies (mAbs) Biosimilars Market Size by Country
7.3.1 Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2021-2032)
7.3.2 Germany Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
7.3.3 France Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
7.3.5 Russia Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
7.3.6 Italy Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Market Size by Region
8.3.1 Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Region (2021-2032)
8.3.2 China Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
8.3.3 Japan Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
8.3.4 South Korea Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
8.3.5 India Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
8.3.7 Australia Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2021-2032)
9.2 South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2021-2032)
9.3 South America Monoclonal Antibodies (mAbs) Biosimilars Market Size by Country
9.3.1 South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2021-2032)
9.3.2 Brazil Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
9.3.3 Argentina Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Market Size by Country
10.3.1 Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2021-2032)
10.3.2 Turkey Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
10.3.4 UAE Monoclonal Antibodies (mAbs) Biosimilars Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Monoclonal Antibodies (mAbs) Biosimilars Market Drivers
11.2 Monoclonal Antibodies (mAbs) Biosimilars Market Restraints
11.3 Monoclonal Antibodies (mAbs) Biosimilars Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Monoclonal Antibodies (mAbs) Biosimilars Industry Chain
12.2 Monoclonal Antibodies (mAbs) Biosimilars Upstream Analysis
12.3 Monoclonal Antibodies (mAbs) Biosimilars Midstream Analysis
12.4 Monoclonal Antibodies (mAbs) Biosimilars Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 3. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Molecular Target, (USD Million), 2021 & 2025 & 2032
Table 4. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Celltrion,Inc. Company Information, Head Office, and Major Competitors
Table 8. Celltrion,Inc. Major Business
Table 9. Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 10. Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Celltrion,Inc. Recent Developments and Future Plans
Table 12. SamsungBioepisCo.,Ltd. Company Information, Head Office, and Major Competitors
Table 13. SamsungBioepisCo.,Ltd. Major Business
Table 14. SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 15. SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. SamsungBioepisCo.,Ltd. Recent Developments and Future Plans
Table 17. AmgenInc. Company Information, Head Office, and Major Competitors
Table 18. AmgenInc. Major Business
Table 19. AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 20. AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. SandozGroupAG Company Information, Head Office, and Major Competitors
Table 22. SandozGroupAG Major Business
Table 23. SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 24. SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. SandozGroupAG Recent Developments and Future Plans
Table 26. PfizerInc. Company Information, Head Office, and Major Competitors
Table 27. PfizerInc. Major Business
Table 28. PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 29. PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. PfizerInc. Recent Developments and Future Plans
Table 31. BioconBiologicsLimited Company Information, Head Office, and Major Competitors
Table 32. BioconBiologicsLimited Major Business
Table 33. BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 34. BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. BioconBiologicsLimited Recent Developments and Future Plans
Table 36. FreseniusKabiAG Company Information, Head Office, and Major Competitors
Table 37. FreseniusKabiAG Major Business
Table 38. FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 39. FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. FreseniusKabiAG Recent Developments and Future Plans
Table 41. FormyconAG Company Information, Head Office, and Major Competitors
Table 42. FormyconAG Major Business
Table 43. FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 44. FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. FormyconAG Recent Developments and Future Plans
Table 46. Alvotech Company Information, Head Office, and Major Competitors
Table 47. Alvotech Major Business
Table 48. Alvotech Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 49. Alvotech Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Alvotech Recent Developments and Future Plans
Table 51. TevaPharmaceuticalIndustriesLtd. Company Information, Head Office, and Major Competitors
Table 52. TevaPharmaceuticalIndustriesLtd. Major Business
Table 53. TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 54. TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. TevaPharmaceuticalIndustriesLtd. Recent Developments and Future Plans
Table 56. Organon&Co. Company Information, Head Office, and Major Competitors
Table 57. Organon&Co. Major Business
Table 58. Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 59. Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. Organon&Co. Recent Developments and Future Plans
Table 61. BoehringerIngelheimInternationalGmbH Company Information, Head Office, and Major Competitors
Table 62. BoehringerIngelheimInternationalGmbH Major Business
Table 63. BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 64. BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. BoehringerIngelheimInternationalGmbH Recent Developments and Future Plans
Table 66. CoherusBioSciences,Inc. Company Information, Head Office, and Major Competitors
Table 67. CoherusBioSciences,Inc. Major Business
Table 68. CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 69. CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. CoherusBioSciences,Inc. Recent Developments and Future Plans
Table 71. mAbxience Company Information, Head Office, and Major Competitors
Table 72. mAbxience Major Business
Table 73. mAbxience Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 74. mAbxience Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. mAbxience Recent Developments and Future Plans
Table 76. STADAArzneimittelAG Company Information, Head Office, and Major Competitors
Table 77. STADAArzneimittelAG Major Business
Table 78. STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 79. STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 80. STADAArzneimittelAG Recent Developments and Future Plans
Table 81. GedeonRichterPlc. Company Information, Head Office, and Major Competitors
Table 82. GedeonRichterPlc. Major Business
Table 83. GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 84. GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. GedeonRichterPlc. Recent Developments and Future Plans
Table 86. Bio-TheraSolutions,Ltd. Company Information, Head Office, and Major Competitors
Table 87. Bio-TheraSolutions,Ltd. Major Business
Table 88. Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 89. Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 90. Bio-TheraSolutions,Ltd. Recent Developments and Future Plans
Table 91. ShanghaiHenliusBiotech,Inc. Company Information, Head Office, and Major Competitors
Table 92. ShanghaiHenliusBiotech,Inc. Major Business
Table 93. ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 94. ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 95. ShanghaiHenliusBiotech,Inc. Recent Developments and Future Plans
Table 96. QiluPharmaceuticalCo.,Ltd. Company Information, Head Office, and Major Competitors
Table 97. QiluPharmaceuticalCo.,Ltd. Major Business
Table 98. QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 99. QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 100. QiluPharmaceuticalCo.,Ltd. Recent Developments and Future Plans
Table 101. InnoventBiologics,Inc. Company Information, Head Office, and Major Competitors
Table 102. InnoventBiologics,Inc. Major Business
Table 103. InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 104. InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 105. InnoventBiologics,Inc. Recent Developments and Future Plans
Table 106. Dr.Reddy’sLaboratoriesLtd. Company Information, Head Office, and Major Competitors
Table 107. Dr.Reddy’sLaboratoriesLtd. Major Business
Table 108. Dr.Reddy’sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 109. Dr.Reddy’sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 110. Dr.Reddy’sLaboratoriesLtd. Recent Developments and Future Plans
Table 111. IntasPharmaceuticalsLtd. Company Information, Head Office, and Major Competitors
Table 112. IntasPharmaceuticalsLtd. Major Business
Table 113. IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 114. IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. IntasPharmaceuticalsLtd. Recent Developments and Future Plans
Table 116. AccordHealthcare Company Information, Head Office, and Major Competitors
Table 117. AccordHealthcare Major Business
Table 118. AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 119. AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 120. AccordHealthcare Recent Developments and Future Plans
Table 121. LupinLimited Company Information, Head Office, and Major Competitors
Table 122. LupinLimited Major Business
Table 123. LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 124. LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 125. LupinLimited Recent Developments and Future Plans
Table 126. ZydusLifesciencesLimited Company Information, Head Office, and Major Competitors
Table 127. ZydusLifesciencesLimited Major Business
Table 128. ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 129. ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 130. ZydusLifesciencesLimited Recent Developments and Future Plans
Table 131. RelianceLifeSciencesPvt.Ltd. Company Information, Head Office, and Major Competitors
Table 132. RelianceLifeSciencesPvt.Ltd. Major Business
Table 133. RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 134. RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 135. RelianceLifeSciencesPvt.Ltd. Recent Developments and Future Plans
Table 136. PrestigeBiopharmaLimited Company Information, Head Office, and Major Competitors
Table 137. PrestigeBiopharmaLimited Major Business
Table 138. PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 139. PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 140. PrestigeBiopharmaLimited Recent Developments and Future Plans
Table 141. AmnealPharmaceuticals,Inc. Company Information, Head Office, and Major Competitors
Table 142. AmnealPharmaceuticals,Inc. Major Business
Table 143. AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 144. AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. AmnealPharmaceuticals,Inc. Recent Developments and Future Plans
Table 146. PolpharmaBiologicsB.V. Company Information, Head Office, and Major Competitors
Table 147. PolpharmaBiologicsB.V. Major Business
Table 148. PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 149. PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 150. PolpharmaBiologicsB.V. Recent Developments and Future Plans
Table 151. Mabwell(Shanghai)BioscienceCo.,Ltd. Company Information, Head Office, and Major Competitors
Table 152. Mabwell(Shanghai)BioscienceCo.,Ltd. Major Business
Table 153. Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 154. Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 155. Mabwell(Shanghai)BioscienceCo.,Ltd. Recent Developments and Future Plans
Table 156. ZhejiangHisunPharmaceuticalCo.,Ltd. Company Information, Head Office, and Major Competitors
Table 157. ZhejiangHisunPharmaceuticalCo.,Ltd. Major Business
Table 158. ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 159. ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 160. ZhejiangHisunPharmaceuticalCo.,Ltd. Recent Developments and Future Plans
Table 161. JiangsuHengruiPharmaceuticalsCo.,Ltd. Company Information, Head Office, and Major Competitors
Table 162. JiangsuHengruiPharmaceuticalsCo.,Ltd. Major Business
Table 163. JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 164. JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 165. JiangsuHengruiPharmaceuticalsCo.,Ltd. Recent Developments and Future Plans
Table 166. LivzonPharmaceuticalGroupInc. Company Information, Head Office, and Major Competitors
Table 167. LivzonPharmaceuticalGroupInc. Major Business
Table 168. LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 169. LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 170. LivzonPharmaceuticalGroupInc. Recent Developments and Future Plans
Table 171. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Company Information, Head Office, and Major Competitors
Table 172. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Major Business
Table 173. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 174. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 175. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Recent Developments and Future Plans
Table 176. MabpharmLimited Company Information, Head Office, and Major Competitors
Table 177. MabpharmLimited Major Business
Table 178. MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 179. MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 180. MabpharmLimited Recent Developments and Future Plans
Table 181. BioXpressTherapeuticsSA Company Information, Head Office, and Major Competitors
Table 182. BioXpressTherapeuticsSA Major Business
Table 183. BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 184. BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 185. BioXpressTherapeuticsSA Recent Developments and Future Plans
Table 186. TanvexBioPharma,Inc. Company Information, Head Office, and Major Competitors
Table 187. TanvexBioPharma,Inc. Major Business
Table 188. TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 189. TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 190. TanvexBioPharma,Inc. Recent Developments and Future Plans
Table 191. CelltrionHealthcare Company Information, Head Office, and Major Competitors
Table 192. CelltrionHealthcare Major Business
Table 193. CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 194. CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 195. CelltrionHealthcare Recent Developments and Future Plans
Table 196. AmegaBiotech Company Information, Head Office, and Major Competitors
Table 197. AmegaBiotech Major Business
Table 198. AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 199. AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 200. AmegaBiotech Recent Developments and Future Plans
Table 201. ProbiomedS.A.deC.V. Company Information, Head Office, and Major Competitors
Table 202. ProbiomedS.A.deC.V. Major Business
Table 203. ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 204. ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 205. ProbiomedS.A.deC.V. Recent Developments and Future Plans
Table 206. Global Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million) by Players (2021-2026)
Table 207. Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Share by Players (2021-2026)
Table 208. Breakdown of Monoclonal Antibodies (mAbs) Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3)
Table 209. Market Position of Players in Monoclonal Antibodies (mAbs) Biosimilars, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 210. Head Office of Key Monoclonal Antibodies (mAbs) Biosimilars Players
Table 211. Monoclonal Antibodies (mAbs) Biosimilars Market: Company Product Type Footprint
Table 212. Monoclonal Antibodies (mAbs) Biosimilars Market: Company Product Application Footprint
Table 213. Monoclonal Antibodies (mAbs) Biosimilars New Market Entrants and Barriers to Market Entry
Table 214. Monoclonal Antibodies (mAbs) Biosimilars Mergers, Acquisition, Agreements, and Collaborations
Table 215. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (USD Million) by Type (2021-2026)
Table 216. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Share by Type (2021-2026)
Table 217. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Forecast by Type (2027-2032)
Table 218. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2021-2026)
Table 219. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Forecast by Application (2027-2032)
Table 220. North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2021-2026) & (USD Million)
Table 221. North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2027-2032) & (USD Million)
Table 222. North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2021-2026) & (USD Million)
Table 223. North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2027-2032) & (USD Million)
Table 224. North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2021-2026) & (USD Million)
Table 225. North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2027-2032) & (USD Million)
Table 226. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2021-2026) & (USD Million)
Table 227. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2027-2032) & (USD Million)
Table 228. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2021-2026) & (USD Million)
Table 229. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2027-2032) & (USD Million)
Table 230. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2021-2026) & (USD Million)
Table 231. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2027-2032) & (USD Million)
Table 232. Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2021-2026) & (USD Million)
Table 233. Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2027-2032) & (USD Million)
Table 234. Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2021-2026) & (USD Million)
Table 235. Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2027-2032) & (USD Million)
Table 236. Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Region (2021-2026) & (USD Million)
Table 237. Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Region (2027-2032) & (USD Million)
Table 238. South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2021-2026) & (USD Million)
Table 239. South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2027-2032) & (USD Million)
Table 240. South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2021-2026) & (USD Million)
Table 241. South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2027-2032) & (USD Million)
Table 242. South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2021-2026) & (USD Million)
Table 243. South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2027-2032) & (USD Million)
Table 244. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2021-2026) & (USD Million)
Table 245. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2027-2032) & (USD Million)
Table 246. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2021-2026) & (USD Million)
Table 247. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2027-2032) & (USD Million)
Table 248. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2021-2026) & (USD Million)
Table 249. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2027-2032) & (USD Million)
Table 250. Global Key Players of Monoclonal Antibodies (mAbs) Biosimilars Upstream (Raw Materials)
Table 251. Global Monoclonal Antibodies (mAbs) Biosimilars Typical Customers
Table 1. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 3. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Molecular Target, (USD Million), 2021 & 2025 & 2032
Table 4. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Celltrion,Inc. Company Information, Head Office, and Major Competitors
Table 8. Celltrion,Inc. Major Business
Table 9. Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 10. Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Celltrion,Inc. Recent Developments and Future Plans
Table 12. SamsungBioepisCo.,Ltd. Company Information, Head Office, and Major Competitors
Table 13. SamsungBioepisCo.,Ltd. Major Business
Table 14. SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 15. SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. SamsungBioepisCo.,Ltd. Recent Developments and Future Plans
Table 17. AmgenInc. Company Information, Head Office, and Major Competitors
Table 18. AmgenInc. Major Business
Table 19. AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 20. AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. SandozGroupAG Company Information, Head Office, and Major Competitors
Table 22. SandozGroupAG Major Business
Table 23. SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 24. SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. SandozGroupAG Recent Developments and Future Plans
Table 26. PfizerInc. Company Information, Head Office, and Major Competitors
Table 27. PfizerInc. Major Business
Table 28. PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 29. PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. PfizerInc. Recent Developments and Future Plans
Table 31. BioconBiologicsLimited Company Information, Head Office, and Major Competitors
Table 32. BioconBiologicsLimited Major Business
Table 33. BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 34. BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. BioconBiologicsLimited Recent Developments and Future Plans
Table 36. FreseniusKabiAG Company Information, Head Office, and Major Competitors
Table 37. FreseniusKabiAG Major Business
Table 38. FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 39. FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. FreseniusKabiAG Recent Developments and Future Plans
Table 41. FormyconAG Company Information, Head Office, and Major Competitors
Table 42. FormyconAG Major Business
Table 43. FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 44. FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. FormyconAG Recent Developments and Future Plans
Table 46. Alvotech Company Information, Head Office, and Major Competitors
Table 47. Alvotech Major Business
Table 48. Alvotech Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 49. Alvotech Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Alvotech Recent Developments and Future Plans
Table 51. TevaPharmaceuticalIndustriesLtd. Company Information, Head Office, and Major Competitors
Table 52. TevaPharmaceuticalIndustriesLtd. Major Business
Table 53. TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 54. TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. TevaPharmaceuticalIndustriesLtd. Recent Developments and Future Plans
Table 56. Organon&Co. Company Information, Head Office, and Major Competitors
Table 57. Organon&Co. Major Business
Table 58. Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 59. Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. Organon&Co. Recent Developments and Future Plans
Table 61. BoehringerIngelheimInternationalGmbH Company Information, Head Office, and Major Competitors
Table 62. BoehringerIngelheimInternationalGmbH Major Business
Table 63. BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 64. BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. BoehringerIngelheimInternationalGmbH Recent Developments and Future Plans
Table 66. CoherusBioSciences,Inc. Company Information, Head Office, and Major Competitors
Table 67. CoherusBioSciences,Inc. Major Business
Table 68. CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 69. CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. CoherusBioSciences,Inc. Recent Developments and Future Plans
Table 71. mAbxience Company Information, Head Office, and Major Competitors
Table 72. mAbxience Major Business
Table 73. mAbxience Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 74. mAbxience Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. mAbxience Recent Developments and Future Plans
Table 76. STADAArzneimittelAG Company Information, Head Office, and Major Competitors
Table 77. STADAArzneimittelAG Major Business
Table 78. STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 79. STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 80. STADAArzneimittelAG Recent Developments and Future Plans
Table 81. GedeonRichterPlc. Company Information, Head Office, and Major Competitors
Table 82. GedeonRichterPlc. Major Business
Table 83. GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 84. GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. GedeonRichterPlc. Recent Developments and Future Plans
Table 86. Bio-TheraSolutions,Ltd. Company Information, Head Office, and Major Competitors
Table 87. Bio-TheraSolutions,Ltd. Major Business
Table 88. Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 89. Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 90. Bio-TheraSolutions,Ltd. Recent Developments and Future Plans
Table 91. ShanghaiHenliusBiotech,Inc. Company Information, Head Office, and Major Competitors
Table 92. ShanghaiHenliusBiotech,Inc. Major Business
Table 93. ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 94. ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 95. ShanghaiHenliusBiotech,Inc. Recent Developments and Future Plans
Table 96. QiluPharmaceuticalCo.,Ltd. Company Information, Head Office, and Major Competitors
Table 97. QiluPharmaceuticalCo.,Ltd. Major Business
Table 98. QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 99. QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 100. QiluPharmaceuticalCo.,Ltd. Recent Developments and Future Plans
Table 101. InnoventBiologics,Inc. Company Information, Head Office, and Major Competitors
Table 102. InnoventBiologics,Inc. Major Business
Table 103. InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 104. InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 105. InnoventBiologics,Inc. Recent Developments and Future Plans
Table 106. Dr.Reddy’sLaboratoriesLtd. Company Information, Head Office, and Major Competitors
Table 107. Dr.Reddy’sLaboratoriesLtd. Major Business
Table 108. Dr.Reddy’sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 109. Dr.Reddy’sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 110. Dr.Reddy’sLaboratoriesLtd. Recent Developments and Future Plans
Table 111. IntasPharmaceuticalsLtd. Company Information, Head Office, and Major Competitors
Table 112. IntasPharmaceuticalsLtd. Major Business
Table 113. IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 114. IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. IntasPharmaceuticalsLtd. Recent Developments and Future Plans
Table 116. AccordHealthcare Company Information, Head Office, and Major Competitors
Table 117. AccordHealthcare Major Business
Table 118. AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 119. AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 120. AccordHealthcare Recent Developments and Future Plans
Table 121. LupinLimited Company Information, Head Office, and Major Competitors
Table 122. LupinLimited Major Business
Table 123. LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 124. LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 125. LupinLimited Recent Developments and Future Plans
Table 126. ZydusLifesciencesLimited Company Information, Head Office, and Major Competitors
Table 127. ZydusLifesciencesLimited Major Business
Table 128. ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 129. ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 130. ZydusLifesciencesLimited Recent Developments and Future Plans
Table 131. RelianceLifeSciencesPvt.Ltd. Company Information, Head Office, and Major Competitors
Table 132. RelianceLifeSciencesPvt.Ltd. Major Business
Table 133. RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 134. RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 135. RelianceLifeSciencesPvt.Ltd. Recent Developments and Future Plans
Table 136. PrestigeBiopharmaLimited Company Information, Head Office, and Major Competitors
Table 137. PrestigeBiopharmaLimited Major Business
Table 138. PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 139. PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 140. PrestigeBiopharmaLimited Recent Developments and Future Plans
Table 141. AmnealPharmaceuticals,Inc. Company Information, Head Office, and Major Competitors
Table 142. AmnealPharmaceuticals,Inc. Major Business
Table 143. AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 144. AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. AmnealPharmaceuticals,Inc. Recent Developments and Future Plans
Table 146. PolpharmaBiologicsB.V. Company Information, Head Office, and Major Competitors
Table 147. PolpharmaBiologicsB.V. Major Business
Table 148. PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 149. PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 150. PolpharmaBiologicsB.V. Recent Developments and Future Plans
Table 151. Mabwell(Shanghai)BioscienceCo.,Ltd. Company Information, Head Office, and Major Competitors
Table 152. Mabwell(Shanghai)BioscienceCo.,Ltd. Major Business
Table 153. Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 154. Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 155. Mabwell(Shanghai)BioscienceCo.,Ltd. Recent Developments and Future Plans
Table 156. ZhejiangHisunPharmaceuticalCo.,Ltd. Company Information, Head Office, and Major Competitors
Table 157. ZhejiangHisunPharmaceuticalCo.,Ltd. Major Business
Table 158. ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 159. ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 160. ZhejiangHisunPharmaceuticalCo.,Ltd. Recent Developments and Future Plans
Table 161. JiangsuHengruiPharmaceuticalsCo.,Ltd. Company Information, Head Office, and Major Competitors
Table 162. JiangsuHengruiPharmaceuticalsCo.,Ltd. Major Business
Table 163. JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 164. JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 165. JiangsuHengruiPharmaceuticalsCo.,Ltd. Recent Developments and Future Plans
Table 166. LivzonPharmaceuticalGroupInc. Company Information, Head Office, and Major Competitors
Table 167. LivzonPharmaceuticalGroupInc. Major Business
Table 168. LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 169. LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 170. LivzonPharmaceuticalGroupInc. Recent Developments and Future Plans
Table 171. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Company Information, Head Office, and Major Competitors
Table 172. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Major Business
Table 173. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 174. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 175. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Recent Developments and Future Plans
Table 176. MabpharmLimited Company Information, Head Office, and Major Competitors
Table 177. MabpharmLimited Major Business
Table 178. MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 179. MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 180. MabpharmLimited Recent Developments and Future Plans
Table 181. BioXpressTherapeuticsSA Company Information, Head Office, and Major Competitors
Table 182. BioXpressTherapeuticsSA Major Business
Table 183. BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 184. BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 185. BioXpressTherapeuticsSA Recent Developments and Future Plans
Table 186. TanvexBioPharma,Inc. Company Information, Head Office, and Major Competitors
Table 187. TanvexBioPharma,Inc. Major Business
Table 188. TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 189. TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 190. TanvexBioPharma,Inc. Recent Developments and Future Plans
Table 191. CelltrionHealthcare Company Information, Head Office, and Major Competitors
Table 192. CelltrionHealthcare Major Business
Table 193. CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 194. CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 195. CelltrionHealthcare Recent Developments and Future Plans
Table 196. AmegaBiotech Company Information, Head Office, and Major Competitors
Table 197. AmegaBiotech Major Business
Table 198. AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 199. AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 200. AmegaBiotech Recent Developments and Future Plans
Table 201. ProbiomedS.A.deC.V. Company Information, Head Office, and Major Competitors
Table 202. ProbiomedS.A.deC.V. Major Business
Table 203. ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Product and Solutions
Table 204. ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 205. ProbiomedS.A.deC.V. Recent Developments and Future Plans
Table 206. Global Monoclonal Antibodies (mAbs) Biosimilars Revenue (USD Million) by Players (2021-2026)
Table 207. Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Share by Players (2021-2026)
Table 208. Breakdown of Monoclonal Antibodies (mAbs) Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3)
Table 209. Market Position of Players in Monoclonal Antibodies (mAbs) Biosimilars, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 210. Head Office of Key Monoclonal Antibodies (mAbs) Biosimilars Players
Table 211. Monoclonal Antibodies (mAbs) Biosimilars Market: Company Product Type Footprint
Table 212. Monoclonal Antibodies (mAbs) Biosimilars Market: Company Product Application Footprint
Table 213. Monoclonal Antibodies (mAbs) Biosimilars New Market Entrants and Barriers to Market Entry
Table 214. Monoclonal Antibodies (mAbs) Biosimilars Mergers, Acquisition, Agreements, and Collaborations
Table 215. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (USD Million) by Type (2021-2026)
Table 216. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Share by Type (2021-2026)
Table 217. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Forecast by Type (2027-2032)
Table 218. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2021-2026)
Table 219. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Forecast by Application (2027-2032)
Table 220. North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2021-2026) & (USD Million)
Table 221. North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2027-2032) & (USD Million)
Table 222. North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2021-2026) & (USD Million)
Table 223. North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2027-2032) & (USD Million)
Table 224. North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2021-2026) & (USD Million)
Table 225. North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2027-2032) & (USD Million)
Table 226. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2021-2026) & (USD Million)
Table 227. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2027-2032) & (USD Million)
Table 228. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2021-2026) & (USD Million)
Table 229. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2027-2032) & (USD Million)
Table 230. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2021-2026) & (USD Million)
Table 231. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2027-2032) & (USD Million)
Table 232. Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2021-2026) & (USD Million)
Table 233. Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2027-2032) & (USD Million)
Table 234. Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2021-2026) & (USD Million)
Table 235. Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2027-2032) & (USD Million)
Table 236. Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Region (2021-2026) & (USD Million)
Table 237. Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Region (2027-2032) & (USD Million)
Table 238. South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2021-2026) & (USD Million)
Table 239. South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2027-2032) & (USD Million)
Table 240. South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2021-2026) & (USD Million)
Table 241. South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2027-2032) & (USD Million)
Table 242. South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2021-2026) & (USD Million)
Table 243. South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2027-2032) & (USD Million)
Table 244. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2021-2026) & (USD Million)
Table 245. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type (2027-2032) & (USD Million)
Table 246. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2021-2026) & (USD Million)
Table 247. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application (2027-2032) & (USD Million)
Table 248. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2021-2026) & (USD Million)
Table 249. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Country (2027-2032) & (USD Million)
Table 250. Global Key Players of Monoclonal Antibodies (mAbs) Biosimilars Upstream (Raw Materials)
Table 251. Global Monoclonal Antibodies (mAbs) Biosimilars Typical Customers
LIST OF FIGURES
Figure 1. Monoclonal Antibodies (mAbs) Biosimilars Picture
Figure 2. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Type in 2025
Figure 4. Adalimumab Biosimilars
Figure 5. Infliximab Biosimilars
Figure 6. Rituximab Biosimilars
Figure 7. Trastuzumab Biosimilars
Figure 8. Bevacizumab Biosimilars
Figure 9. Ranibizumab Biosimilars
Figure 10. Ustekinumab Biosimilars
Figure 11. Tocilizumab Biosimilars
Figure 12. Denosumab Biosimilars
Figure 13. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 14. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Dosage Form in 2025
Figure 15. Intravenous Infusion Vials
Figure 16. Subcutaneous Prefilled Syringes
Figure 17. Autoinjectors
Figure 18. Lyophilized Powder for Injection
Figure 19. Concentrate for Solution for Infusion
Figure 20. Ophthalmic Intravitreal Injection
Figure 21. Multiple Presentations
Figure 22. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Molecular Target, (USD Million), 2021 & 2025 & 2032
Figure 23. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Molecular Target in 2025
Figure 24. TNF-? Inhibitors
Figure 25. CD20-targeting Antibodies
Figure 26. HER2-targeting Antibodies
Figure 27. VEGF/VEGF-A Inhibitors
Figure 28. IL-6R Inhibitors
Figure 29. IL-12/23 Inhibitors
Figure 30. RANKL Inhibitors
Figure 31. C5 Complement Inhibitors
Figure 32. IgE Inhibitors
Figure 33. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 34. Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Application in 2025
Figure 35. Oncology Picture
Figure 36. Autoimmune and Inflammatory Diseases Picture
Figure 37. Ophthalmology Picture
Figure 38. Bone Disease and Osteoporosis Picture
Figure 39. Hematology and Rare Diseases Picture
Figure 40. Asthma and Allergy Picture
Figure 41. Other Picture
Figure 42. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 43. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 44. Global Market Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 45. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Region (2021-2032)
Figure 46. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Region in 2025
Figure 47. North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 48. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 49. Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 50. South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 51. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 52. Company Three Recent Developments and Future Plans
Figure 53. Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Share by Players in 2025
Figure 54. Monoclonal Antibodies (mAbs) Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 55. Market Share of Monoclonal Antibodies (mAbs) Biosimilars by Player Revenue in 2025
Figure 56. Top 3 Monoclonal Antibodies (mAbs) Biosimilars Players Market Share in 2025
Figure 57. Top 6 Monoclonal Antibodies (mAbs) Biosimilars Players Market Share in 2025
Figure 58. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Share by Type (2021-2026)
Figure 59. Global Monoclonal Antibodies (mAbs) Biosimilars Market Share Forecast by Type (2027-2032)
Figure 60. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Share by Application (2021-2026)
Figure 61. Global Monoclonal Antibodies (mAbs) Biosimilars Market Share Forecast by Application (2027-2032)
Figure 62. North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Type (2021-2032)
Figure 63. North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Application (2021-2032)
Figure 64. North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Country (2021-2032)
Figure 65. United States Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 66. Canada Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 67. Mexico Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 68. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Type (2021-2032)
Figure 69. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Application (2021-2032)
Figure 70. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Country (2021-2032)
Figure 71. Germany Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 72. France Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 73. United Kingdom Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 74. Russia Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 75. Italy Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 76. Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Type (2021-2032)
Figure 77. Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Application (2021-2032)
Figure 78. Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Region (2021-2032)
Figure 79. China Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 80. Japan Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 81. South Korea Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 82. India Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 83. Southeast Asia Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 84. Australia Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 85. South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Type (2021-2032)
Figure 86. South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Application (2021-2032)
Figure 87. South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Country (2021-2032)
Figure 88. Brazil Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 89. Argentina Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 90. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Type (2021-2032)
Figure 91. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Application (2021-2032)
Figure 92. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Country (2021-2032)
Figure 93. Turkey Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 94. Saudi Arabia Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 95. UAE Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 96. Monoclonal Antibodies (mAbs) Biosimilars Market Drivers
Figure 97. Monoclonal Antibodies (mAbs) Biosimilars Market Restraints
Figure 98. Monoclonal Antibodies (mAbs) Biosimilars Market Trends
Figure 99. Porters Five Forces Analysis
Figure 100. Monoclonal Antibodies (mAbs) Biosimilars Industrial Chain
Figure 101. Methodology
Figure 102. Research Process and Data Source
Figure 1. Monoclonal Antibodies (mAbs) Biosimilars Picture
Figure 2. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Type in 2025
Figure 4. Adalimumab Biosimilars
Figure 5. Infliximab Biosimilars
Figure 6. Rituximab Biosimilars
Figure 7. Trastuzumab Biosimilars
Figure 8. Bevacizumab Biosimilars
Figure 9. Ranibizumab Biosimilars
Figure 10. Ustekinumab Biosimilars
Figure 11. Tocilizumab Biosimilars
Figure 12. Denosumab Biosimilars
Figure 13. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 14. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Dosage Form in 2025
Figure 15. Intravenous Infusion Vials
Figure 16. Subcutaneous Prefilled Syringes
Figure 17. Autoinjectors
Figure 18. Lyophilized Powder for Injection
Figure 19. Concentrate for Solution for Infusion
Figure 20. Ophthalmic Intravitreal Injection
Figure 21. Multiple Presentations
Figure 22. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Molecular Target, (USD Million), 2021 & 2025 & 2032
Figure 23. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Molecular Target in 2025
Figure 24. TNF-? Inhibitors
Figure 25. CD20-targeting Antibodies
Figure 26. HER2-targeting Antibodies
Figure 27. VEGF/VEGF-A Inhibitors
Figure 28. IL-6R Inhibitors
Figure 29. IL-12/23 Inhibitors
Figure 30. RANKL Inhibitors
Figure 31. C5 Complement Inhibitors
Figure 32. IgE Inhibitors
Figure 33. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 34. Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Application in 2025
Figure 35. Oncology Picture
Figure 36. Autoimmune and Inflammatory Diseases Picture
Figure 37. Ophthalmology Picture
Figure 38. Bone Disease and Osteoporosis Picture
Figure 39. Hematology and Rare Diseases Picture
Figure 40. Asthma and Allergy Picture
Figure 41. Other Picture
Figure 42. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 43. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 44. Global Market Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 45. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Region (2021-2032)
Figure 46. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Region in 2025
Figure 47. North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 48. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 49. Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 50. South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 51. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 52. Company Three Recent Developments and Future Plans
Figure 53. Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Share by Players in 2025
Figure 54. Monoclonal Antibodies (mAbs) Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 55. Market Share of Monoclonal Antibodies (mAbs) Biosimilars by Player Revenue in 2025
Figure 56. Top 3 Monoclonal Antibodies (mAbs) Biosimilars Players Market Share in 2025
Figure 57. Top 6 Monoclonal Antibodies (mAbs) Biosimilars Players Market Share in 2025
Figure 58. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Share by Type (2021-2026)
Figure 59. Global Monoclonal Antibodies (mAbs) Biosimilars Market Share Forecast by Type (2027-2032)
Figure 60. Global Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Share by Application (2021-2026)
Figure 61. Global Monoclonal Antibodies (mAbs) Biosimilars Market Share Forecast by Application (2027-2032)
Figure 62. North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Type (2021-2032)
Figure 63. North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Application (2021-2032)
Figure 64. North America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Country (2021-2032)
Figure 65. United States Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 66. Canada Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 67. Mexico Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 68. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Type (2021-2032)
Figure 69. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Application (2021-2032)
Figure 70. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Country (2021-2032)
Figure 71. Germany Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 72. France Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 73. United Kingdom Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 74. Russia Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 75. Italy Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 76. Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Type (2021-2032)
Figure 77. Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Application (2021-2032)
Figure 78. Asia-Pacific Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Region (2021-2032)
Figure 79. China Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 80. Japan Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 81. South Korea Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 82. India Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 83. Southeast Asia Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 84. Australia Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 85. South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Type (2021-2032)
Figure 86. South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Application (2021-2032)
Figure 87. South America Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Country (2021-2032)
Figure 88. Brazil Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 89. Argentina Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 90. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Type (2021-2032)
Figure 91. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Application (2021-2032)
Figure 92. Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Country (2021-2032)
Figure 93. Turkey Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 94. Saudi Arabia Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 95. UAE Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 96. Monoclonal Antibodies (mAbs) Biosimilars Market Drivers
Figure 97. Monoclonal Antibodies (mAbs) Biosimilars Market Restraints
Figure 98. Monoclonal Antibodies (mAbs) Biosimilars Market Trends
Figure 99. Porters Five Forces Analysis
Figure 100. Monoclonal Antibodies (mAbs) Biosimilars Industrial Chain
Figure 101. Methodology
Figure 102. Research Process and Data Source
